Literature DB >> 28338407

Optimizing a Retention Strategy with Young People for BRIGHTLIGHT, a Longitudinal Cohort Study Examining the Value of Specialist Cancer Care for Young People.

Rachel M Taylor1, Natasha Aslam1, Sarah Lea2, Jeremy S Whelan1, Lorna A Fern1.   

Abstract

PURPOSE: To maximize retention of participants in a longitudinal cohort study, we sought to understand young peoples' views about barriers and facilitators to continuing study participation.
METHODS: Ten young people with a previous cancer diagnosis aged 15-24 participated in a 1 day workshop. The workshop used participatory methodology consisting of three exercises as follows: role play/scene setting; force field analysis of research participation in small groups; and focus group discussion. A final prioritization exercise was administered individually after the workshop.
RESULTS: Twenty-four barriers to maintaining participation were summarized in five themes as follows: life commitments; concerns specific to the study; emotional barriers; practical barriers; and other reasons. The top 3 specific barriers were as follows: not a priority/other things are more important; too time consuming; and forgetting/memory. The top 3 facilitators for participation were as follows: wishing to help other young people; giving back to the cancer community; and honoring an initial commitment to participation. The top 3 suggested solutions to encourage continued participation were as follows: reminder text message or email before each survey to check preferred method of delivery; breaking up the online survey into modules to make completion less overwhelming; and consolidation of study information in one location.
CONCLUSION: Involving young people in designing a retention strategy for young people with cancer has informed the BRIGHTLIGHT retention strategy. Patient and public involvement is imperative for successful research but measuring impact is challenging. The success of implementing the changes to optimize retention was shown in the increase in retention in Wave 3 from 30% to final participation of 58%.

Entities:  

Keywords:  BRIGHTLIGHT; cohort study; longitudinal research; patient involvement/engagement; retention

Mesh:

Year:  2017        PMID: 28338407     DOI: 10.1089/jayao.2016.0085

Source DB:  PubMed          Journal:  J Adolesc Young Adult Oncol        ISSN: 2156-5333            Impact factor:   2.223


  5 in total

1.  Description of the BRIGHTLIGHT cohort: the evaluation of teenage and young adult cancer services in England.

Authors:  Rachel M Taylor; Lorna A Fern; Julie Barber; Javier Alvarez-Galvez; Richard Feltbower; Stephen Morris; Louise Hooker; Martin G McCabe; Faith Gibson; Rosalind Raine; Dan P Stark; Jeremy S Whelan
Journal:  BMJ Open       Date:  2019-04-20       Impact factor: 2.692

2.  BRIGHTLIGHT researchers as 'dramaturgs': creating There is a Light from complex research data.

Authors:  Rachel M Taylor; Brian Lobel; Keisha Thompson; Adura Onashile; Mark Croasdale; Nathaniel Hall; Faith Gibson; Ana Martins; David Wright; Sue Morgan; Jeremy S Whelan; Lorna A Fern
Journal:  Res Involv Engagem       Date:  2020-08-10

3.  Involving young people in BRIGHTLIGHT from study inception to secondary data analysis: insights from 10 years of user involvement.

Authors:  Rachel M Taylor; Jeremy S Whelan; Faith Gibson; Sue Morgan; Lorna A Fern
Journal:  Res Involv Engagem       Date:  2018-12-27

4.  Instagram as a tool for study engagement and community building among adolescents: A social media pilot study.

Authors:  Veronica L Thomas; Marisol Chavez; Erica N Browne; Alexandra M Minnis
Journal:  Digit Health       Date:  2020-03-17

5.  Longitudinal cohort study of the impact of specialist cancer services for teenagers and young adults on quality of life: outcomes from the BRIGHTLIGHT study.

Authors:  Rachel M Taylor; Lorna A Fern; Julie Barber; Javier Alvarez-Galvez; Richard Feltbower; Sarah Lea; Ana Martins; Stephen Morris; Louise Hooker; Faith Gibson; Rosalind Raine; Dan P Stark; Jeremy Whelan
Journal:  BMJ Open       Date:  2020-11-26       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.